Prothena Corp PLC (PRTA)

53.83
0.76 1.39
NASDAQ : Health Care
Prev Close 54.59
Open 54.32
Day Low/High 53.00 / 54.56
52 Wk Low/High 28.20 / 76.42
Volume 353.76K
Avg Volume 293.20K
Exchange NASDAQ
Shares Outstanding 38.28M
Market Cap 2.11B
EPS -4.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Prothena To Present New Research On Cardiac Biomarker NT-proBNP In AL Amyloidosis At HFSA Annual Meeting

Prothena Reports Second Quarter 2017 Financial Results And Provides R&D Update
Prothena To Report Second Quarter 2017 Financial Results On August 8

Prothena To Report Second Quarter 2017 Financial Results On August 8

These Are the Best Growth Stocks Right Now in Biotech

These Are the Best Growth Stocks Right Now in Biotech

Top names.

Prothena Announces Initiation Of Phase 2 PASADENA Study Of PRX002/RG7935 In Patients With Early Parkinson's Disease

Prothena Announces Initiation Of Phase 2 PASADENA Study Of PRX002/RG7935 In Patients With Early Parkinson's Disease

3 Stocks You Probably Never Heard Of Could Catch Fire Soon

3 Stocks You Probably Never Heard Of Could Catch Fire Soon

Six charts showing signs of smart money footprints.

Prothena Announces Appointment Of Wagner Zago, PhD As Chief Scientific Officer

Prothena Announces Appointment Of Sarah Noonberg, MD, PhD As Chief Medical Officer

Prothena Reports First Quarter 2017 Financial Results And Provides R&D Update

Prothena To Report First Quarter 2017 Financial Results On May 9

Prothena To Participate In The Deutsche Bank 42nd Annual Health Care Conference

Clinical Results Presented From Prothena's Phase 1b Study Of PRX002/RG7935 Demonstrating Robust Antibody CNS Penetration And Significant Reduction Of Free Serum Alpha-synuclein In Patients With Parkinson's Disease

Results For Prothena's Phase 1b Multiple Ascending Dose Study Of PRX002/RG7935 In Patients With Parkinson's Disease To Be Presented At The 13th¿ International Conference On Alzheimer's And Parkinson's Diseases

Prothena Raises $155.3M to Bring Anti-Organ Failure Drug to Market

Prothena Raises $155.3M to Bring Anti-Organ Failure Drug to Market

The biotech company plans to commercialize its treatment for AL amyloidosis, a disease that causes protein to build up in the blood.

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

Karyopharm Therapeutics falls 18%; Lexicon rises on drug approval.

Prothena Announces Pricing Of Public Offering Of 2,700,000 Ordinary Shares

Prothena Announces Public Offering Of Ordinary Shares

Prothena Reports Fourth Quarter And Full Year 2016 Financial Results, And Provides Financial Guidance And R&D Update

Prothena To Participate In The Leerink Partners 6th Annual Global Healthcare Conference

Prothena To Report Fourth Quarter And Full Year 2016 Financial Results And Host Webcast Conference Call On February 14

Prothena To Participate In The J.P. Morgan Healthcare Conference

Prothena To Participate In The J.P. Morgan Healthcare Conference

Prothena Announces Appointment Of Chief Regulatory Officer

Prothena Announces Appointment Of Chief Regulatory Officer

First-In-Human Assessment Of PRX002, Prothena's Anti-Alpha Synuclein Antibody For Parkinson's Disease, Published In Movement Disorders Journal

First-In-Human Assessment Of PRX002, Prothena's Anti-Alpha Synuclein Antibody For Parkinson's Disease, Published In Movement Disorders Journal

Data Previously Presented in 2015 at 19th International Congress of Parkinson's Disease and Movement Disorders

Prothena Reports Results From Phase 1b Study Of PRX002 Demonstrating Robust Antibody CNS Penetration And Significant Reduction Of Free Serum Alpha-synuclein In Patients With Parkinson's Disease

Prothena Reports Results From Phase 1b Study Of PRX002 Demonstrating Robust Antibody CNS Penetration And Significant Reduction Of Free Serum Alpha-synuclein In Patients With Parkinson's Disease

Data For Prothena's NEOD001 To Be Presented At The 58th Annual American Society Of Hematology Meeting

Data For Prothena's NEOD001 To Be Presented At The 58th Annual American Society Of Hematology Meeting

Prothena Reports Third Quarter 2016 Financial Results And Provides R&D Update

Prothena Reports Third Quarter 2016 Financial Results And Provides R&D Update

Prothena To Report Third Quarter 2016 Financial Results On November 1

Prothena To Report Third Quarter 2016 Financial Results On November 1

Prothena Announces Appointment Of Dr. Gene G. Kinney As President, Chief Executive Officer And Director

Prothena Announces Appointment Of Dr. Gene G. Kinney As President, Chief Executive Officer And Director

In Memoriam - Friend, Scientific Innovator And Leader Dr. Dale B. Schenk Has Passed Away

In Memoriam - Friend, Scientific Innovator And Leader Dr. Dale B. Schenk Has Passed Away

Prothena Outlines Phase 2 Development Strategy For PRX003

Prothena Outlines Phase 2 Development Strategy For PRX003

Load More
Quant Rating on 4:00 PM EDT 8/21/2017

D

(Sell)

From Our Partners

Evercore ISI initiates 14 bullish calls, 9 neutral
SeekingAlpha

Prothena initiated with an Outperform at Evercore ISI
The Fly

Prothena beats by $0.42, beats on revenue
SeekingAlpha

Notable earnings after Tuesday’s close
SeekingAlpha

Prothena initiated with a Buy at Jefferies
The Fly

Prothena announces mid-stage initiation of Parkinson's drug
SeekingAlpha

Feared short seller Carson Block's next target is this biotech stock
CNBC

Prothena claws back from bearish report from short seller, down 3%
SeekingAlpha

Prothena slumps 4% on Muddy Waters short position, doubts efficacy of lead product candidate
SeekingAlpha

Premarket analyst action - healthcare
SeekingAlpha

Prothena initiated with a Buy at BTIG
The Fly

New medical chief at Prothena
SeekingAlpha

Safety concerns with Ionis' inotersen makes Prothena worth a look - Piper
SeekingAlpha

Piper Jaffray sees positive readthrough for Prothena from Ionis data
The Fly

Prothena has positive read through from Ionis safety issues, says SunTrust
The Fly
TheStreet Quant Rating: D (Sell)

Get the (PRTA)
Report Here

Trending
This Is Where McDonald's Is Closing a Lot of Restaurants
Panera Bread's Founder Reveals Why Chain Is Putting Sugar Counts on Soda Cups
J.C. Penney Won't Die, So Buy Its Stock
Ken Doctor: Looking Behind Tronc's Surprising Clean Sweep At L.A. Times
Tesla Should Be Terrified By What's Happening to Its Stock